Clinical Expert Commentaries

Clinical Expert Commentaries published on January 7, 2019
In this activity, Dr. Sagar Lonial provides an overview of the key presentations at this year's ASH annual meeting, including ways to enhance the efficacy of induction therapy and RRMM.

To view accredited ASH Highlights, please click here.

Clinical Expert Commentaries published on January 7, 2019
In this activity, Dr. Saad Usmani provides an overview of the key late-breaking presentation from ASH on the phase 3 study of D-Rd vs. Rd in patients with NDMM ineligible for transplant.

To view accredited ASH Highlights, please click here.

Clinical Expert Commentaries published on November 19, 2018
Dr. Kumar discusses the recent FDA approval of elotuzumab in combination with pomalidomide and dexamethasone, and what this means for your patients with relapsed/refractory multiple myeloma.
Clinical Expert Commentaries published on August 29, 2018
Dr. Michele Cavo summarizes important updates from key trials in multiple myeloma, as presented at the 2018 EHA Annual Meeting.
Clinical Expert Commentaries published on May 18, 2018
Dr. Joshua Richter discusses the changing management of multiple myeloma, including recent advances in immunotherapy, CAR T-cell therapy, and bifunctional antibodies.
Clinical Expert Commentaries published on July 26, 2017
Dr. Stuart Goldberg discusses a patient survey tool that helps determine the best time to initiate end-of-life care discussions with your terminal cancer patients.
Clinical Expert Commentaries published on March 7, 2014 in General Education
Dr. Robert Kyle discusses the discovery and history of therapeutic agents for multiple myeloma.
Dr. Shaji Kumar defines clinical trial endpoints and how each endpoint is evaluated.
Clinical Expert Commentaries published on July 2, 2013 in Response Assessment
Sandra Kurtin discusses the management and risk reduction strategies associated with carfilzomib.
Clinical Expert Commentaries published on June 28, 2013 in Response Assessment
Sandra Kurtin discusses the management and risk reduction strategies associated with pomalidomide.
Page 1 of 4
Results 1 - 10 of 32